Surveillance Summary March 13 – 19, 2004
March 19, 2004 by admin · Leave a Comment
Our emerging health technology database experienced light activity throughout Week 12 of 2004 with 10 technology updates. 8 Moderate Impact Technologies and 2 Low Impact Technologies were updated. None of the 10 updates were for newly detected technologies and, for the first time in 2004, no technology updates occurred in the High Impact category. Mean Impact Score for the week was 37, the lowest mean experienced in 2004. Please see the table below for this week’s top ten technologies to watch.
Week at a Glance
Technologies updated this week in the BioHorizon database
Technology Company Target Disease Score
Zenapax Protein Design Labs Asthma 50/100
Dexanabinol Pharmos Traumatic Brain Injury 51/100
tgAAC94 Targeted Genetics Rheumatoid Arthritis 45/100
PA-457 Panacos HIV 43/100
R112 Rigel Pharma Allergic Rhinitis 40/100
MVA-HPV-IL2 Transgene HPV/cervical cancer 40/100
XL 119 Exelixis Hepatobiliary Cancer 36/100
MLN2704 Millenium Prostate Cancer 34/100
Tarceva™ OSI Phamaceuticals Non Small Cell Lung Cancer 33/100
Tezacitabine Chiron Gastroesophageal Cancer 1/100
